ArticleThe World Allergy Organization journal2017
Knowledge and management of chronic spontaneous urticaria in Latin America: a cross-sectional study in Ecuador.
Article in The World Allergy Organization journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- Why physicians underuse patient-reported outcomes in atopic dermatitis and chronic urticaria - Insights from the UCARE/ADCARE PROMUSE study.The World Allergy Organization journal · 2026Article
- Feasibility and Patient Experiences in a WhatsApp-Based Educational Pilot for Spanish-Speaking Adults With Chronic Spontaneous Urticaria.International journal of dermatology · 2026Article
- Targeting Cytokine Dysregulation in Psoriasis: The Role of Dietary Interventions in Modulating the Immune Response.International journal of molecular sciences · 2025Review
- Physician estimation of the prevalence and clinical impact of chronic urticaria: results of the global, multicenter UCARE CU-PAPER study.Frontiers in allergy · 2025Article
- Cost-of-illness analysis of chronic urticaria clinical management in five countries of Latin America.Clinical and translational allergy · 2025Article
- A Patient Charter for Chronic Urticaria.Advances in therapy · 2024Article
- Urticaria.Nature reviews. Disease primers · 2022Review
- Multicentric and Observational Study of Omalizumab for Chronic Spontaneous Urticaria in Real-Life in Colombia.Frontiers in allergy · 2022Article
- Clinical characteristics and management of chronic spontaneous urticaria in patients refractory to HThe World Allergy Organization journal · 2020Article
- A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real-world study in Belgium.Journal of the European Academy of Dermatology and Venereology : JEADV · 2020Observational
- Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America.The World Allergy Organization journal · 2019Article
- Etiology of chronic urticaria: the Ecuadorian experience.The World Allergy Organization journal · 2018Article
- Differences in chronic spontaneous urticaria between Europe and Central/South America: results of the multi-center real world AWARE study.The World Allergy Organization journal · 2018Article
- Management of chronic spontaneous urticaria: a worldwide perspective.The World Allergy Organization journal · 2018Article
- Clinical Characteristics of Patients with Chronic Urticaria and Adherence to Management Guidelines by Postgraduate Students in Dermatology: A Retrospective Single Center Study.Indian journal of dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe current EAACI/GA
methodsWe investigated physicians who treat CsU patients in a cross-sectional study using a standardized questionnaire. Descriptive statistics were employed, adjusted logistic regression was performed to assess the link of guideline knowledge and use of therapy.
resultsSeven hundred forty surveys were collected and analyzed. The mean age of physicians was 42.3 (±12.5) years. Most of the participants (65.1%) were general physicians (GP), 13.7% were pediatricians, 11.0% internists, 6.8% dermatologists or allergists (D/A). Only 18.8% knew the EAACI/GA
conclusionThis study shows that the knowledge of guideline recommendations in physicians who treat urticaria patients in Ecuador is low. The diagnostic workup and treatment of CsU patients are largely not in line with guideline recommendations in real life practice settings. We were able to compare results between German and Ecuadorian physicians and found that Ecuadorian physicians have lower awareness of the current guideline (33 vs 18%). Only one-third of physicians reported using regular doses of sgAHs as the first line treatment. Also, only 12.9% of physicians use sgAHs in higher doses and physicians still use fgAHs, particularly pediatricians (42.9%). Our results suggest that disparities in knowledge between physicians from different countries could influence the management of CsU. Knowledge of the guidelines is linked to better choices of treatments. Awareness of guidelines needs to be promoted for better management of chronic urticaria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.